PLIANT THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
PLIANT THERAPEUTICS, INC. (PLRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$41.49 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2023-11-09
- PLIANT THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$41.49M.
- PLIANT THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$41.19M.
- PLIANT THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-03-31 was -$37.55M.
- PLIANT THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was -$35.06M.
- PLIANT THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$123.32M.
- PLIANT THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$97.26M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$41.49M 10-Q · filed 2023-11-09 | -$82.68M derived: sum of 2 quarters · filed 2023-11-09 | -$120.23M 10-Q · filed 2023-11-09 | -$155.29M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | -$41.19M 10-Q · filed 2023-08-09 | -$78.74M 10-Q · filed 2023-08-09 | -$113.80M derived: sum of 3 quarters · filed 2023-08-09 | -$144.41M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-03-31 | -$37.55M 10-Q · filed 2023-05-09 | -$72.61M derived: sum of 2 quarters · filed 2023-05-09 | -$103.22M derived: sum of 3 quarters · filed 2023-11-09 | -$132.77M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | -$35.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$65.67M derived: sum of 2 quarters · filed 2023-11-09 | -$95.22M derived: sum of 3 quarters · filed 2023-11-09 | -$123.32M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$30.61M 10-Q · filed 2023-11-09 | -$60.16M derived: sum of 2 quarters · filed 2023-11-09 | -$88.26M 10-Q · filed 2023-11-09 | -$112.79M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$29.55M 10-Q · filed 2023-08-09 | -$57.65M 10-Q · filed 2023-08-09 | -$82.18M derived: sum of 3 quarters · filed 2023-08-09 | -$109.22M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$28.10M 10-Q · filed 2023-05-09 | -$52.63M derived: sum of 2 quarters · filed 2023-05-09 | -$79.68M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$24.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$51.58M derived: sum of 2 quarters · filed 2023-03-09 | -$97.26M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$27.05M 10-Q · filed 2022-11-08 | -$72.73M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |